Login Register Cart 0
Review Article

Drugs or Mechanical Devices for Obstructive LUTS?

Author(s): Evangelos N. Symeonidis and Petros Sountoulides*

Volume 21, Issue 15, 2020

Page: [1537 - 1549] Pages: 13

DOI: 10.2174/1389450121666200630111723

Price: $65

Abstract

Lower urinary tract symptoms (LUTS) secondary to benign prostate obstruction (BPO) afflict a very large part of the population on a global scale. Urologists confront patients with a diversity of BPH-related symptoms in their daily practice. For years, the cornerstone of obstructive BPH treatment consisted of mostly medical and to a lesser extent surgical therapies. However, while medical treatment has come to a standstill, over the last decade, new minimally invasive surgical therapies (MISTs) have emerged, conferring several possible advantages over conventional transurethral resection of the prostate (TURP). MISTs have also demonstrated the ability to better respect and preserve sexual function while providing safety and minimal morbidity. Their long-term efficacy and durability over drug therapy remain debatable, as is the need for secondary procedures. In the present paper, we aim to offer a narrative summary of the available literature, thus providing an indirect comparative assessment of drugs and MISTs for obstructive LUTS.

Keywords: LUTS, drugs, pharmacotherapy, minimally invasive therapies, mechanical devices, benign prostate obstruction, BPH.

« Previous Next »
Graphical Abstract

[1]
Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4(3): 148-51.
[http://dx.doi.org/10.1016/j.ajur.2017.06.004] [PMID: 29264223]
[2]
Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJMCH, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 2010; 28(1): 3-8.
[http://dx.doi.org/10.1007/s00345-009-0480-3] [PMID: 19816692]
[3]
Sountoulides P, Karatzas A, Gravas S. Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. Ther Adv Urol 2019.111756287219828971
[http://dx.doi.org/10.1177/1756287219828971] [PMID: 30792821]
[4]
Das AK, Leong JY, Roehrborn CG. Office-based therapies for benign prostatic hyperplasia: a review and update. Can J Urol 2019; 26(4)(Suppl. 1): 2-7.
[PMID: 31481142]
[5]
Pham H, Sharma P. Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. Can J Urol 2018; 25(2): 9228-37.
[PMID: 29679999]
[6]
EAU [Internet] https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-Neurogenic-Male-LUTS-2019.pdf [cited 2020 Jun 11]. Available from:
[7]
Foster HE, Dahm P, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol 2019; 202(3): 592-8.
[http://dx.doi.org/10.1097/JU.0000000000000319] [PMID: 31059668]
[8]
Rukstalis D, Grier D, Stroup SP, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis 2019; 22(3): 411-9.
[http://dx.doi.org/10.1038/s41391-018-0118-x] [PMID: 30542055]
[9]
Woo HH, Chin PT, McNicholas TA, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011; 108(1): 82-8.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10342.x] [PMID: 21554526]
[10]
Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012; 79(1): 5-11.
[http://dx.doi.org/10.1016/j.urology.2011.10.021] [PMID: 22202539]
[11]
McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 2013; 64(2): 292-9.
[http://dx.doi.org/10.1016/j.eururo.2013.01.008] [PMID: 23357348]
[12]
Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 2014; 113(4): 615-22.
[http://dx.doi.org/10.1111/bju.12540] [PMID: 24765680]
[13]
Rukstalis D, Rashid P, Bogache WK, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int 2016; 118(Suppl. 3): 14-22.
[http://dx.doi.org/10.1111/bju.13666] [PMID: 27684483]
[14]
Shore N. A review of the prostatic urethral lift for lower urinary tract symptoms: Symptom relief, flow improvement, and preservation of sexual function in men with benign prostatic hyperplasia. Curr Bladder Dysfunct Rep 2015; 10(2): 186-92.
[http://dx.doi.org/10.1007/s11884-015-0296-5] [PMID: 25984251]
[15]
Perera M, Roberts MJ, Doi SAR, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 2015; 67(4): 704-13.
[http://dx.doi.org/10.1016/j.eururo.2014.10.031] [PMID: 25466940]
[16]
Jones P, Rajkumar GN, Rai BP, et al. Medium-term outcomes of urolift (Minimum 12 Months Follow-up): Evidence from a systematic review. Urology 2016; 97: 20-4.
[http://dx.doi.org/10.1016/j.urology.2016.05.003] [PMID: 27208817]
[17]
Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 2015; 68(4): 643-52.
[http://dx.doi.org/10.1016/j.eururo.2015.04.024] [PMID: 25937539]
[18]
Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017; 119(5): 767-75.
[http://dx.doi.org/10.1111/bju.13714] [PMID: 27862831]
[19]
Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol 2013; 190(6): 2161-7.
[http://dx.doi.org/10.1016/j.juro.2013.05.116] [PMID: 23764081]
[20]
Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 2015; 22(3): 7772-82.
[PMID: 26068624]
[21]
Roehrborn CG. Prostatic urethral lift: A unique minimally invasive surgical treatment of male lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol Clin North Am 2016; 43(3): 357-69.
[http://dx.doi.org/10.1016/j.ucl.2016.04.008] [PMID: 27476128]
[22]
Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24(3): 8802-13.
[PMID: 28646935]
[23]
McVary KT, Gange SN, Shore ND, et al. L.I.F.T. Study Investigators. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med 2014; 11(1): 279-87.
[http://dx.doi.org/10.1111/jsm.12333] [PMID: 24119101]
[24]
Sievert K-D, Schonthaler M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 2019; 37(7): 1353-60.
[http://dx.doi.org/10.1007/s00345-018-2494-1] [PMID: 30283994]
[25]
Gupta NK, Gange SN, McVary KT. New and emerging technologies in treatment of lower urinary tract symptoms from benign prostatic hyperplasia. Sex Med Rev 2019; 7(3): 491-8.
[http://dx.doi.org/10.1016/j.sxmr.2018.02.003] [PMID: 29606553]
[26]
McVary KT, Holland B, Beahrs JR. Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2020; 23(2): 303-8.
[http://dx.doi.org/10.1038/s41391-019-0187-5] [PMID: 31740738]
[27]
Roehrborn CG, Gange SN, Gittelman MC, et al. Convective thermal therapy: durable 2-Year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2017; 197(6): 1507-16.
[http://dx.doi.org/10.1016/j.juro.2016.12.045] [PMID: 27993667]
[28]
McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195(5): 1529-38.
[http://dx.doi.org/10.1016/j.juro.2015.10.181] [PMID: 26614889]
[29]
Darson MF, Alexander EE, Schiffman ZJ, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol 2017; 9: 159-68.
[http://dx.doi.org/10.2147/RRU.S143679] [PMID: 28861405]
[30]
Dixon CM, Cedano ER, Pacik D, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol 2016; 8: 207-16.
[http://dx.doi.org/10.2147/RRU.S119596] [PMID: 27921028]
[31]
McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-Year results from randomized controlled study. Urology 2019; 126: 171-9.
[http://dx.doi.org/10.1016/j.urology.2018.12.041] [PMID: 30677455]
[32]
McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 2018; 111: 1-9.
[http://dx.doi.org/10.1016/j.urology.2017.10.023] [PMID: 29122620]
[33]
Porpiglia F, Fiori C, Bertolo R, et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 2018; 122(1): 106-12.
[http://dx.doi.org/10.1111/bju.14141] [PMID: 29359881]
[34]
Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int 2015; 116(2): 278-87.
[http://dx.doi.org/10.1111/bju.12982] [PMID: 25382816]
[35]
Bertolo R, Fiori C, Amparore D, Porpiglia F. Follow-up of temporary implantable nitinol device (TIND) implantation for the treatment of BPH: a Systematic Review. Curr Urol Rep 2018; 19(6): 44.
[http://dx.doi.org/10.1007/s11934-018-0793-0] [PMID: 29700686]
[36]
Amparore D, De Cillis S, Volpi G, et al. ESUT Group First- and second-generation temporary implantable nitinol devices as minimally invasive treatments for BPH-Related LUTS: Systematic review of the literature. Curr Urol Rep 2019; 20(8): 47.
[http://dx.doi.org/10.1007/s11934-019-0912-6] [PMID: 31278441]
[37]
Porpiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int 2019; 123(6): 1061-9.
[http://dx.doi.org/10.1111/bju.14608] [PMID: 30382600]
[38]
Kadner G, Valerio M, Giannakis I, et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol 2020.
[http://dx.doi.org/10.1007/s00345-020-03140-z] [PMID: 32124019]
[39]
Marcon J, Magistro G, Stief CG, Grimm T. What’s New in TIND? Eur Urol Focus 2018; 4(1): 40-2.
[http://dx.doi.org/10.1016/j.euf.2018.04.009] [PMID: 29705283]
[40]
Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J 2018; 12(10): 303-12.
[http://dx.doi.org/10.5489/cuaj.5616] [PMID: 30332601]
[41]
Sountoulides P, Gravas S. The impact of combination therapy with a-Blockers and 5ARIs on the progression of BPH. Curr Drug Targets 2015; 16(11): 1172-9.
[http://dx.doi.org/10.2174/1389450116666150223164032] [PMID: 25706255]
[42]
Roehrborn CG, Siami P, Barkin J, et al. CombAT study group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57(1): 123-31.
[http://dx.doi.org/10.1016/j.eururo.2009.09.035] [PMID: 19825505]
[43]
Pirozzi L, Sountoulides P, Castellan P, et al. Current pharmacological treatment for male LUTS due to BPH: Dutasteride or Finasteride? Curr Drug Targets 2015; 16(11): 1165-71.
[http://dx.doi.org/10.2174/1389450116666150518101617] [PMID: 25981606]
[44]
Cindolo L, Fanizza C, Romero M, et al. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol 2013; 31(3): 665-71.
[http://dx.doi.org/10.1007/s00345-012-1000-4] [PMID: 23239103]
[45]
O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92(3): 262-6.
[http://dx.doi.org/10.1046/j.1464-410X.2003.04310.x] [PMID: 12887480]
[46]
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108(3): 388-94.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10195.x] [PMID: 21631695]
[47]
McConnell JD, Bruskewitz R, Walsh P, et al. Finasteride long-term efficacy and safety study group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338(9): 557-63.
[http://dx.doi.org/10.1056/NEJM199802263380901] [PMID: 9475762]
[48]
Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract 2012; 66(11): 1052-5.
[http://dx.doi.org/10.1111/j.1742-1241.2012.03010.x] [PMID: 23067029]
[49]
McConnell JD, Roehrborn CG, Bautista OM, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349(25): 2387-98.
[http://dx.doi.org/10.1056/NEJMoa030656] [PMID: 14681504]
[50]
Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and tamsulosin (CombAT) trial. BJU Int 2011; 107(6): 946-54.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10124.x] [PMID: 21332630]
[51]
Montorsi F, Roehrborn C, Garcia-Penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the combination of avodart and tamsulosin (CombAT) study. BJU Int 2011; 107(9): 1426-31.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10129.x] [PMID: 21348912]
[52]
Dimitropoulos K, Gravas S. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol 2016; 8(1): 19-28.
[http://dx.doi.org/10.1177/1756287215607419] [PMID: 26834837]
[53]
Kawabe K, Yoshida M, Homma Y. Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98(5): 1019-24.
[http://dx.doi.org/10.1111/j.1464-410X.2006.06448.x] [PMID: 16945121]
[54]
Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91(1): 41-4.
[http://dx.doi.org/10.1046/j.1464-410X.2003.03077.x] [PMID: 12614248]
[55]
Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61(5): 917-25.
[http://dx.doi.org/10.1016/j.eururo.2012.01.013] [PMID: 22297243]
[56]
Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013; 63(1): 158-65.
[http://dx.doi.org/10.1016/j.eururo.2012.07.003] [PMID: 22831853]
[57]
Nagasubramanian S, John NT, Antonisamy B, et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int 2020; 125(5): 718-24.
[http://dx.doi.org/10.1111/bju.15027] [PMID: 32012409]

Rights & Permissions Print Cite
Article Metrics
12
© 2024 Bentham Science Publishers | Privacy Policy